A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma

Inclusion Criteria:

- Histologically confirmed melanoma of cutaneous origin

- Participants with BRAFV600 mutation-positive, cutaneous melanoma (either pathologic
Stage IIC or Stage III according to AJCC Staging Criteria version 7 that has been
completely resected

- BRAF V600 mutation status of the current primary tumor or involved lymph node
determined to be positive using the cobas BRAF V600 mutation test

- Surgically rendered free of disease within 90 days of randomization

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Life expectancy of at least 5 years

- Fully recovered from the effects of any major surgery or significant traumatic injury
prior to the first dose of study treatment

- Adequate hematologic, hepatic, and renal function

Exclusion Criteria:

- History of any systemic or local therapy (e.g., chemotherapy, biologic or targeted
therapy, hormonal therapy, or photodynamic therapy) for the treatment or prevention of
melanoma, including interferon alpha-2b and pegylated interferon alpha-2b

- History of limb perfusion therapy

- History of radiotherapy for the treatment of melanoma

- Invasive malignancy other than melanoma at the time of enrollment or within 5 years
prior to first dose of study treatment

- Family history of inherited colon cancer syndromes

- Known personal history of >3 adenomatous colorectal polyps or a personal history of
adenomatous colorectal polyp(s) >2 centimeters (cm) in size

- History of or current clinical, radiographic, or pathologic evidence of in-transit
metastases, satellite, or microsatellite lesions

- History of or current clinical, radiographic, or pathologic evidence of recurrent
lymph node involvement after resection of a primary melanoma with lymph node
involvement at any time in the past

- History of local and/or regional and/or distant melanoma recurrence

- History or current radiographic or pathologic evidence of distant metastases

- History of clinically significant cardiac or pulmonary dysfunction

- Major surgical procedure or significant traumatic injury within 4 weeks prior to first
dose of study treatment

- Infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C virus